Caldera Medical Acquires Ethicon’s GYNECARE TVT ™ Family of Products in Transformational Expansion Globally for Women’s Health Company
Caldera Medical, a leader in women's health medical devices, has acquired Ethicon’s Gynecare TVT™ family of products and will transition the products in the coming months. This strategic milestone builds on Caldera Medical’s 23-year commitment to delivering best-in-class therapies that improve the quality of life for women worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250320644274/en/
Caldera Medical is expanding its commitment to women’s health with the acquisition of Ethicon’s Gynecare TVT™ family of products! With over two decades of clinical data and trusted efficacy, TVT has been a gold standard in minimally invasive treatment for stress urinary incontinence (SUI). This acquisition ensures a seamless transition for surgeons, patients, and partners, as we maintain the same manufacturing, materials, and dedicated team behind these life-changing products. Our mission is clear: expanding access to proven pelvic health solutions and improving the quality of life for women worldwide.
The TVT product line - consisting of TVT, TVT Exact, TVT-O and TVT Abbrevo, provides minimally invasive treatment options for women with stress urinary incontinence (SUI). As part of the acquisition, Caldera Medical will maintain the same manufacturing facility, materials, and dedicated manufacturing team behind the TVT products, ensuring a seamless transition for surgeons, patients, and partners. With more than two decades of clinical data, including 20-year patient follow-up, the trusted performance and efficacy of TVT remain unchanged.
“This acquisition marks a significant advancement in our mission to transform women’s health,” said Bryon Merade, CEO of Caldera Medical. “By bringing the TVT product line into our portfolio, we reinforce our unwavering commitment to providing safe, effective solutions for surgeons and their patients. We are honored to build on the legacy and expand the reach of this esteemed product family, delivering proven treatments to more women around the world.”
Caldera Medical will expand global customer support for TVT over the next several months and invest in advancing care for a greater number of women. Combining Caldera Medical’s established expertise in pelvic health with TVT’s demonstrated success, the company further solidifies its position as a premier provider of advanced solutions for women. This acquisition follows the September 2023 acquisition of Atlantic Therapeutics with the Innovo non-invasive solution for bladder leaks and the October 2024 acquisition of UVision360 with the Luminelle product line for hysteroscopy and cystoscopy. These acquisitions not only accelerate Caldera Medical’s growth but underscore its dedication to broadening access to life-changing treatments, backed by a legacy of clinical success and a focus on improving patient outcomes.
About Caldera Medical
Caldera Medical is a leading innovator in the field of women’s health, specializing in the development, manufacturing, and marketing of advanced medical devices for the treatment of Stress Urinary Incontinence, Pelvic Organ Prolapse, and gynecologic conditions such as polyps and fibroids. With a focus on minimally invasive surgical solutions, Caldera Medical is committed to its mission of improving the quality of life for women globally. In collaboration with its surgeon partners, Caldera Medical operates the largest humanitarian program in women’s health, with the goal of providing care to one million underserved women worldwide by 2027. Learn more atwww.calderamedical.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250320644274/en/
Contacts
Caldera Medical Media Relations
pr@calderamedical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Receives 2025 CDMO Leadership Award in Small Molecule Dosage Form Category28.3.2025 15:22:00 EET | Press release
Altasciences, a nine-time CRO Leadership Award winner, is proud to announce they have been awarded a 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327305519/en/ Altasciences receives a 2025 CDMO Leadership Award in the Small Molecule Dosage Form (North America) category. Altasciences’ CDMO site supports drug development with formulation, manufacturing, and analytical testing—from discovery to commercialization. Their FDA-inspected facility features Grade C cleanrooms, R&D and analytical labs, ICH stability chambers, and a cGMP warehouse. "This recognition reflects our CDMO team’s unwavering dedication and expertise, as well as our unrelenting commitment to advancing drug development in collaboration with leading pharmaceutical and biotech innovators,” says Marie-Hélène Raigneau, Co-Chief Operating Officer at Altasciences. “We are gratefu
SES and SpeQtral Sign MoU to Advance Global Quantum-Secure Communications28.3.2025 14:49:00 EET | Press release
SES and SpeQtral signed a Memorandum of Understanding (MoU) to develop an interoperable Optical Ground Station (OGS) to establish long-distance satellite-based Quantum Key Distribution (QKD) between Asia and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328851677/en/ SES's CEO Adel Al-Saleh and SpeQtral's CEO Chune Yang Lum sign a Memorandum of Understanding to develop an interoperable Optical Ground Station to establish long-distance satellite-based Quantum Key Distribution between Asia and Europe. Under the agreement, the development of an interoperable OGS will enable SES and SpeQtral to connect both companies’ current and future QKD satellite missions, resulting in easier access to, and diversity in the supply of long-distance QKD to end users in Asia, Europe and other future compatible ground stations worldwide. The integration of this proposed OGS with Singapore’s fibre-QKD network will help future customer
SBC Medical Group Holdings Inc. Announces Fourth Quarter and Full Year 2024 Financial Results28.3.2025 13:00:00 EET | Press release
SBC Medical Group Holdings Incorporated (NASDAQ: SBC, “SBC Medical” or the “Company”), a global owner, operator and provider of management services and products to cosmetic treatment centers, today announced its financial results for -the three months ended December 31, 2024 and full year 2024. Fourth Quarter 2024 Highlights Total revenues were $44 million, representing a 29% year-over-year decrease. Gross profit was $34 million, representing a 22% year-over-year decrease. Income from operations was $5 million, representing an 80% year-over-year decrease. EBITDA1, which is calculated by adding depreciation and amortization expense and impairment loss to income from operations was $21 million, representing a 22% year-over-year decrease. EBITDA margin1was 47% for the fourth quarter of 2024, compared to 43% for the fourth quarter of 2023. Net income attributable to SBC Medical Group was $7 million, representing a 54% year-over-year decrease. Earnings per share, which is defined as net inc
SINOVAC Announces New Board Member and Chairman of the Audit Committee28.3.2025 13:00:00 EET | Press release
Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (the “Board”) has appointed Sven H. Borho, CFA, as director to the Board to fill in a vacancy created by a recent resignation. As a qualified audit committee financial expert under Nasdaq Rule 5605, Mr. Borho has also been elected as the Chair of the Audit Committee of the Board. Mr. Borho is a founder and Managing Partner of OrbiMed and has over 30 years of experience investing in the healthcare sector. OrbiMed is a leading healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds and royalty/credit funds. OrbiMed funds have been shareholders of SINOVAC since 2013 and currently hold over 2.7 million shares. Following this appo
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta ® (pertuzumab) Biosimilar Candidate HLX1128.3.2025 12:00:00 EET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for HLX11, an investigational biosimilar of Perjeta® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early-stage breast cancer, and adjuvant treatment for certain HER2-positive early breast cancer, among other indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250328881021/en/ The submission was based on a multicenter, randomized, double-blind, parallel-controlled phase 3 clinical study (NCT05346224) aimed to compare the efficacy and safety of HLX11 with reference Perjeta® (pertuzumab) as a neoadjuvant therapy in patients with HER2-positive, HR-negative early-stage, o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom